Mesoblast Limited vs United Parcel Service Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while United Parcel Service Inc trades at $115.85 (market cap $96.18B). The key difference: United Parcel Service Inc is far larger — about 44.3× Mesoblast Limited's market cap, and United Parcel Service Inc pays a 5.8% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | UPS | |
|---|---|---|
Market Cap | $2.17B | $96.18B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $120.00 |
52-Week Low | $12.88 | $82.58 |
Enterprise Value | $2.17B | $119.04B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.8% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
UPS stock trades at $112.97, down 4.03% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 33.41% ROE and 5.94% net margin, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Recent quarters show consistent earnings beats, with Q2 2026 results expected on July 28, 2026. Analyst sentiment is divided with 42% buy ratings and consensus price target of $112.
UPS faces near-term headwinds from revenue pressure and Amazon's logistics expansion, but cost-cutting initiatives and healthcare investments provide growth catalysts. The stock's current valuation at 19x P/E appears reasonable given strong cash flow generation. Key risks include competitive threats and economic sensitivity, while dividend sustainability remains a focus with the $1.64 per share payout.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →